Lakshmaiah Narayana Jayaram, Mechesso Abraham Fikru, Rather Imran Ibni Gani, Zarena D, Luo Jinghui, Xie Jingwei, Wang Guangshun
Department of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA.
Department of Biotechnology, Dayananda Sagar College of Engineering, Bangalore 560078, India.
Antibiotics (Basel). 2024 Aug 28;13(9):816. doi: 10.3390/antibiotics13090816.
This review describes the discovery, structure, activity, engineered constructs, and applications of KR-12, the smallest antibacterial peptide of human cathelicidin LL-37, the production of which can be induced under sunlight or by vitamin D. It is a moonlighting peptide that shows both antimicrobial and immune-regulatory effects. Compared to LL-37, KR-12 is extremely appealing due to its small size, lack of toxicity, and narrow-spectrum antimicrobial activity. Consequently, various KR-12 peptides have been engineered to tune peptide activity and stability via amino acid substitution, end capping, hybridization, conjugation, sidechain stapling, and backbone macrocyclization. We also mention recently discovered peptides KR-8 and RIK-10 that are shorter than KR-12. Nano-formulation provides an avenue to targeted delivery, controlled release, and increased bioavailability. In addition, KR-12 has been covalently immobilized on biomaterials/medical implants to prevent biofilm formation. These constructs with enhanced potency and stability are demonstrated to eradicate drug-resistant pathogens, disrupt preformed biofilms, neutralize endotoxins, and regulate host immune responses. Also highlighted are the safety and efficacy of these peptides in various topical and systemic animal models. Finaly, we summarize the achievements and discuss future developments of KR-12 peptides as cosmetic preservatives, novel antibiotics, anti-inflammatory peptides, and microbiota-restoring agents.
本综述描述了人源cathelicidin LL-37最小抗菌肽KR-12的发现、结构、活性、工程构建体及应用,其可在阳光下或维生素D诱导下产生。它是一种具有抗菌和免疫调节双重作用的兼职肽。与LL-37相比,KR-12因其尺寸小、无毒性和窄谱抗菌活性而极具吸引力。因此,人们通过氨基酸取代、封端、杂交、偶联、侧链钉扎和主链大环化等方法对各种KR-12肽进行了工程改造,以调节肽的活性和稳定性。我们还提到了最近发现的比KR-12更短的肽KR-8和RIK-10。纳米制剂为靶向递送、控释和提高生物利用度提供了一条途径。此外,KR-12已被共价固定在生物材料/医疗植入物上以防止生物膜形成。这些具有增强效力和稳定性的构建体被证明能够根除耐药病原体、破坏预先形成的生物膜、中和内毒素并调节宿主免疫反应。还强调了这些肽在各种局部和全身动物模型中的安全性和有效性。最后,我们总结了KR-12肽作为化妆品防腐剂、新型抗生素、抗炎肽和微生物群恢复剂的研究成果并讨论了其未来发展。